Research programme - MASP2 protein inhibitors - EvolVeritas
Alternative Names: Research programme - Mannan-binding lectin–associated serine proteinase 2 inhibitors - EvolVeritasLatest Information Update: 07 Nov 2023
At a glance
- Originator Eotvos Lorand University; Institute of Enzymology
- Developer EvolVeritas
- Class Anti-inflammatories; Antithrombotics; Recombinant proteins
- Mechanism of Action MASP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical IgA nephropathy; Reperfusion injury; Thrombosis
Most Recent Events
- 07 Nov 2023 EvolVeritas has patents protection for MASP-2 inhibitors in Hungary prior to November 2023 (EvolVeritas website, November 2023).
- 07 Nov 2023 Preclinical trials in IgA nephropathy in Hungary (unspecified route) prior to November 2023 (EvolVeritas pipeline, November 2023).
- 07 Nov 2023 Preclinical trials in Reperfusion injury (Prevention) in Hungary (unspecified route) prior to November 2023 (EvolVeritas pipeline, November 2023).